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A commentary on
Reduced effect of percutaneous renal den-
ervation on blood pressure in patients
with isolated systolic hypertension
by Ewen, S., Ukena, C., Linz, D.,
Kindermann, I., Cremers, B., Laufs,
U., et al. (2014). Hypertension. doi:
10.1161/HYPERTENSIONAHA.114.04336
Ewen et al. recently reported in the jour-
nal Hypertension that they investigated, for
the first time, the effect of renal denerva-
tion on blood pressure in 63 patients with
isolated systolic hypertension (Ewen et al.,
2014). The authors concluded that renal
denervation reduced office and ambula-
tory blood pressure in patients with iso-
lated systolic hypertension (Ewen et al.,
2014). However, this conclusion may not
be drawn, as renal denervation may not
decrease ambulatory blood pressure in
these patients. The potential risk of renal
denervation may overweigh its benefit in
patients with isolated systolic hyperten-
sion. Therefore, adjusted drug treatment
may be recommended to these patients
before renal denervation.
Ambulatory blood pressure monitor-
ing is the gold standard to diagnose true
hypertension and removes the white coat
effect (Hermida et al., 2013). Ambulatory
blood pressure is superior to office blood
pressure in predicting cardiovascular
events (Staessen et al., 1999) and mor-
tality (Dolan et al., 2005). The 24-h
ambulatory systolic blood pressure in
these 63 patients in Ewen et al.’s report
decreased by 8 ± 8 and 7 ± 8mm Hg at
6 and 12 months respectively after renal
denervation. However, this study lacked a
control group as the authors pointed out as
a limitation. It has been reported that the
sham procedure reduced 24-h ambulatory
systolic blood pressure by 5 ± 15mm Hg
at 6 months (Bhatt et al., 2014). Therefore,
compared with the sham procedure, renal
denervation may not decrease ambula-
tory blood pressure in those patients with
isolated systolic hypertension.
Consequently, the risk posed to patients
with isolated systolic hypertension by renal
denervation may overweigh the minimal
benefit of renal denervation via lower-
ing blood pressure. For example, renal
artery stenosis after renal denervation is
of concern. The renal artery stenosis rate
in the Symplicity HTN trials (N = 45,
106, and 535 for the Symplicity HTN-1,
HTN-2, and HTN-3 trials, respectively)
ranges from 0.3 to 2.2% (Krum et al.,
2009; Esler et al., 2010; Bhatt et al.,
2014). However, more and more stud-
ies with a smaller sample size (Worthley
et al., 2013; Versaci et al., 2014) and
case reports (Kaltenbach et al., 2012;
Vonend et al., 2012; Aguila et al., 2014;
Bacaksiz et al., 2014; Chandra et al., 2014;
Pucci et al., 2014) showed relatively higher
rates of development or progression of
renal artery stenosis after renal dener-
vation. Ewen et al. did not observe any
hemodynamically significant renal artery
stenosis in these 63 patients with isolated
systolic hypertension within 12 months
(Ewen et al., 2014). However, ultrasonog-
raphy, which was used by the authors,
has limitations in detecting renal artery
stenosis (Zhang et al., 2009; Lao et al.,
2011).
Renal denervation is regarded as a
last resort for patients with resistant
hypertension (Persu et al., 2012). It is
reported that about 9% of adults with
hypertension suffer from resistant hyper-
tension (Persell, 2011), which is often
defined as elevated blood pressure despite
treatment with at least 3 antihyperten-
sive agents including a diuretic at max-
imal tolerated or highest recommended
doses (Bohm et al., 2014). The prevalence
of resistant hypertension is likely over-
estimated due to drug non-adherence.
For example, blood pressure in 20 of
65 patients with resistant hypertension
was normalized after witnessed intake
of antihypertensive drugs (Fadl Elmula
et al., 2014). Resistant hypertension has
been classified as “true” resistant hyper-
tension if blood pressure is still elevated
after witnessed intake of antihyperten-
sive drugs (Fadl Elmula et al., 2014).
Blood pressure in some patients with
“true” resistant hypertension could be
controlled by adjusted drug treatment.
For example, Fadl Elmula et al. reported
that adjusted drug treatment significantly
decreased ambulatory systolic blood pres-
sure from 152 ± 12mm Hg at baseline
to 133 ± 11mm Hg at 6 months in 10
patients with “true” resistant hypertension
(Fadl Elmula et al., 2014). In addition,
adjusted drug treatment lowered ambu-
latory systolic blood pressure to below
135mm Hg in 7 of these 10 patients with
“true” resistant hypertension (Fadl Elmula
et al., 2014). Therefore, patients with iso-
lated systolic hypertension may be offered
with adjusted drug treatment before being
offered with renal denervation.
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In summary, renal denervation may
not decrease ambulatory blood pressure
in patients with isolated systolic hyperten-
sion. Adjusted drug treatment may be rec-
ommended to these patients before renal
denervation, as the risk might overweigh
the benefit of renal denervation in these
patients.
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